Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling

SkylineDx Netherlands United States of America United Kingdom

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in clinical markers and staging systems lead to various interpretations of the high-risk multiple myeloma patient.The gene expression-based signature SKY92 is a standardized and precise tool to identify high-risk myeloma patients with significantly shorter progression-free (PFS) and overall survival (OS).View original content:https://www.prnewswire.co.uk/news-releases/real-world-prospective-data-confirms-improved-risk-stratification-in-multiple-myeloma-using-sky92-gene-expression-profiling-302477613.html